BioSpace News Archive

Proscia ® , a leading provider of digital and computational pathology solutions, has released study results on new technology that leverages artificial intelligence (AI) to automatically detect melanoma, the deadliest form of skin cancer, with a high degree of accuracy.

Diamond Therapeutics Inc. is pleased to announce the appointment of Dr. Torsten Passie to its scientific advisory board.

Baxter Presents Critical Care Data at 34th Annual European Society of Intensive Care Medicine LIVES Congress

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), is pleased to note that its Founded Entity, Vedanta Biosciences (“Vedanta”) today announced that its Phase 2 clinical trial of VE303.

Pulse Biosciences, Inc. today announced the appointment of Laureen DeBuono to its Board of Directors.

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, today announced that its Founded Entity, Sonde Health (“Sonde”), has launched Sonde Mental Fitness, a voice-enabled mental health detection and monitoring technology that uses a brief voice sample to evaluate mental well-being.

CytRx Corporation today announced that Steven A. Kriegsman, Chairman and Chief Executive Officer of CytRx, is scheduled to present at the Virtual LD Micro Main Event XIV, which is being held from October 12-14, 2021.

Pear has built a foundational estate of intellectual property, including more than 20 owned and licensed patents covering more than 600 claims for a variety of different aspects related to prescription digital therapeutics (PDTs).

Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA

Skye Bioscience, Inc. has appointed Kaitlyn Arsenault, CPA, as Chief Financial Officer.